Opioid-Induced Constipation - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018-2020 - ResearchAndMarkets.com
Sep. 07, 2018
DUBLIN--(BUSINESS WIRE)--Sep 7, 2018--The "Opioid-Induced Constipation - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Opioid-Induced Constipation - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 report provides comprehensive insights about marketed and Phase III products for Opioid-Induced Constipation. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.
Coverage of API manufacturers for Opioid-Induced Constipation marketed products spanning across United States, Europe, China and India. The manufacturers' details include manufacturers' names along with their locations.
This report provides a comprehensive understanding of the emerging Phase III therapies for Opioid-Induced Constipation which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.
Key Topics Covered:
1. Report Introduction
2. Opioid-Induced Constipation: OverviewRisk Factors Causes Symptoms Pathophysiology Prognosis Diagnosis Treatment
3. Comparative Analysis of Marketed and Emerging Products
4. Marketed TherapiesProduct Description Route of Synthesis Mechanism of Action Pharmacology Pharmacodynamics Pharmacokinetics Adverse Reactions Clinical Trials Regulatory Milestones Product Development Activities Historical Global Sales Forecasted Global Sales
5. Emerging Therapies (Phase III)Product Description Research and Development Product Development Activities For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/nm372f/opioidinduced?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180907005434/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Gastrointestinal Drugs,Addiction Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/07/2018 02:21 PM/DISC: 09/07/2018 02:21 PM